Literature DB >> 19520673

Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion.

Sarah J White1, Elizabeth M Laurenzana, William Brooks Gentry, Howard P Hendrickson, David Keith Williams, Keith W Ward, Samuel Michael Owens.   

Abstract

Chronic (+)-methamphetamine (METH) use during pregnancy increases the health risk for both mother and fetus. To provide insights into these risks, the relationship between changes in METH disposition and METH-induced pharmacological effects were studied in Sprague-Dawley rat dams and litters. Timed-pregnant rats (n = 5-6) were given saline or METH (5.6-17.8 mg/kg/day) by continuous sc infusion from gestational day (GD) 7 (before organogenesis) until GD21 (0-2 days before delivery). By GD11, all rats in the 17.8-mg/kg/day group died or were sacrificed for humane reasons. There were significant (p < 0.05) dose- and gestational time-dependent decreases in maternal body weight in the 10- to 13.2-mg/kg/day groups, which slowly recovered to near normal by GD21. Continued METH dosing in the surviving groups did not affect the mean pups/litter weight at the end of the experiment on GD21. While maternal and fetal METH and (+)-amphetamine serum concentrations were similar on GD21, brain concentrations were significantly greater in the dams (p < 0.05). Importantly, brain-to-serum ratios in the dams were 9:1 and 3:1 in the pups. METH systemic clearance (Cl(S)) in dams significantly (p < 0.05) decreased from 52 +/- 14 ml/min/kg on GD10 to 28 +/- 6 ml/min/kg on GD21 in all dose groups, indicating late-gestational stage reductions in METH Cl(S). Overall, these findings suggest that there were two periods of increased susceptibility for dams and fetuses during chronic METH treatment. First was the period after the start of METH dosing in which neuroadaptation and tolerance to METH occurs in the adult. The second was at the end of pregnancy when METH clearance was significantly reduced.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520673      PMCID: PMC2726297          DOI: 10.1093/toxsci/kfp127

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  38 in total

Review 1.  Transporters and renal drug elimination.

Authors:  Wooin Lee; Richard B Kim
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

2.  Development of the blood-brain barrier.

Authors:  W Risau; H Wolburg
Journal:  Trends Neurosci       Date:  1990-05       Impact factor: 13.837

3.  Renal autoregulation in midterm and late-pregnant rats.

Authors:  J F Reckelhoff; S D Yokota; C Baylis
Journal:  Am J Obstet Gynecol       Date:  1992-05       Impact factor: 8.661

Review 4.  Pharmacokinetics in pregnancy and placental drug transfer.

Authors:  F Reynolds; C Knott
Journal:  Oxf Rev Reprod Biol       Date:  1989

5.  Postnatal development of rat pups is altered by prenatal methamphetamine exposure.

Authors:  Romana Slamberová; Marie Pometlová; Petra Charousová
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-07-19       Impact factor: 5.067

6.  Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats.

Authors:  K D Acuff-Smith; M A Schilling; J E Fisher; C V Vorhees
Journal:  Neurotoxicol Teratol       Date:  1996 Mar-Apr       Impact factor: 3.763

7.  (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration.

Authors:  W Brooks Gentry; Abid U Ghafoor; William D Wessinger; Elizabeth M Laurenzana; Howard P Hendrickson; S Michael Owens
Journal:  Pharmacol Biochem Behav       Date:  2004-12       Impact factor: 3.533

8.  Maternal hemodynamics and uteroplacental blood flow throughout gestation in conscious rats.

Authors:  R T Dowell; C D Kauer
Journal:  Methods Find Exp Clin Pharmacol       Date:  1997-11

9.  Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection.

Authors:  Howard Hendrickson; Elizabeth Laurenzana; S Michael Owens
Journal:  AAPS J       Date:  2006-11-22       Impact factor: 4.009

10.  Human placental monoamine transporters as targets for amphetamines.

Authors:  J D Ramamoorthy; S Ramamoorthy; F H Leibach; V Ganapathy
Journal:  Am J Obstet Gynecol       Date:  1995-12       Impact factor: 8.661

View more
  3 in total

1.  Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats.

Authors:  Sarah White; Elizabeth Laurenzana; Howard Hendrickson; W Brooks Gentry; S Michael Owens
Journal:  Drug Metab Dispos       Date:  2011-06-01       Impact factor: 3.922

2.  Neonatal +-methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists.

Authors:  Devon L Graham; Robyn M Amos-Kroohs; Amanda A Braun; Curtis E Grace; Tori L Schaefer; Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2012-03-06       Impact factor: 5.176

3.  The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats.

Authors:  Jonathan J Hubbard; Elizabeth M Laurenzana; D Keith Williams; W Brooks Gentry; S Michael Owens
Journal:  J Pharmacol Exp Ther       Date:  2010-10-20       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.